Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma

Lina Zhao, Man Xu, Wen Jiang, Haitao Pan, Jian Zang, Shanquan Luo, Jianhua Wang, Yongchun Zhou, Mei Shi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: The role of induction chemotherapy is less clear in non-endemic locally advanced nanopharyngeal carcinomas (NPC). Results: With a total of 233 eligible patients and a median follow-up of 36 months, 3-year overall survival (OS), local recurrence-free survival (LRFS), distant metastasisfree survival (DMFS), disease free survival (DFS) were 84.5%, 94.9%, 78.6% and 69.2%, respectively. The overall failure rate was 21.0% and distant metastasis occurred in 17.2% patients. Multivariate analyses showed that retropharyngeal and bilateral neck lymph node metastasis were significant prognostic factors for DFS and OS. Moreover, patients receiving both GP (gemcitabine+cisplatin) and TP (docetaxel+cisplatin) regimes had significantly higher DFS and OS compared with PF (cisplatin+5-FU) regime. GP regimes lead to significantly improved OS than TP/PF in some subgroup of patients. No severe toxicities were observed. Materials and Methods: We retrospectively analyzed stage III-IVb NPC patients treated between Jan 2006 and Dec 2014, with induction chemotherapy followed by concurrent chemoradiation (IC-CCRT). Statistical analyses were performed on survival and failure patterns. Conclusions: These results suggested IC-CCRT was safe and effective for NPCs from non-endemic region. The choice of induction regimen appeared to affect patient outcomes.

Original languageEnglish (US)
Pages (from-to)6763-6774
Number of pages12
JournalOncotarget
Volume8
Issue number4
DOIs
StatePublished - Jan 1 2017
Externally publishedYes

Fingerprint

Induction Chemotherapy
Survival
Cisplatin
Disease-Free Survival
docetaxel
gemcitabine
Therapeutics
Neoplasm Metastasis
Carcinoma
Nasopharyngeal carcinoma
Fluorouracil
Neck
Multivariate Analysis
Lymph Nodes
Recurrence

Keywords

  • IMRT
  • Induction chemotherapy
  • Nasopharyngeal carcinoma
  • Non-endemic region
  • WHO II/III

ASJC Scopus subject areas

  • Oncology

Cite this

Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma. / Zhao, Lina; Xu, Man; Jiang, Wen; Pan, Haitao; Zang, Jian; Luo, Shanquan; Wang, Jianhua; Zhou, Yongchun; Shi, Mei.

In: Oncotarget, Vol. 8, No. 4, 01.01.2017, p. 6763-6774.

Research output: Contribution to journalArticle

Zhao, L, Xu, M, Jiang, W, Pan, H, Zang, J, Luo, S, Wang, J, Zhou, Y & Shi, M 2017, 'Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma', Oncotarget, vol. 8, no. 4, pp. 6763-6774. https://doi.org/10.18632/oncotarget.14279
Zhao, Lina ; Xu, Man ; Jiang, Wen ; Pan, Haitao ; Zang, Jian ; Luo, Shanquan ; Wang, Jianhua ; Zhou, Yongchun ; Shi, Mei. / Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma. In: Oncotarget. 2017 ; Vol. 8, No. 4. pp. 6763-6774.
@article{5c737e1585924920901d5cc4bd90edd1,
title = "Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma",
abstract = "Background: The role of induction chemotherapy is less clear in non-endemic locally advanced nanopharyngeal carcinomas (NPC). Results: With a total of 233 eligible patients and a median follow-up of 36 months, 3-year overall survival (OS), local recurrence-free survival (LRFS), distant metastasisfree survival (DMFS), disease free survival (DFS) were 84.5{\%}, 94.9{\%}, 78.6{\%} and 69.2{\%}, respectively. The overall failure rate was 21.0{\%} and distant metastasis occurred in 17.2{\%} patients. Multivariate analyses showed that retropharyngeal and bilateral neck lymph node metastasis were significant prognostic factors for DFS and OS. Moreover, patients receiving both GP (gemcitabine+cisplatin) and TP (docetaxel+cisplatin) regimes had significantly higher DFS and OS compared with PF (cisplatin+5-FU) regime. GP regimes lead to significantly improved OS than TP/PF in some subgroup of patients. No severe toxicities were observed. Materials and Methods: We retrospectively analyzed stage III-IVb NPC patients treated between Jan 2006 and Dec 2014, with induction chemotherapy followed by concurrent chemoradiation (IC-CCRT). Statistical analyses were performed on survival and failure patterns. Conclusions: These results suggested IC-CCRT was safe and effective for NPCs from non-endemic region. The choice of induction regimen appeared to affect patient outcomes.",
keywords = "IMRT, Induction chemotherapy, Nasopharyngeal carcinoma, Non-endemic region, WHO II/III",
author = "Lina Zhao and Man Xu and Wen Jiang and Haitao Pan and Jian Zang and Shanquan Luo and Jianhua Wang and Yongchun Zhou and Mei Shi",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.14279",
language = "English (US)",
volume = "8",
pages = "6763--6774",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "4",

}

TY - JOUR

T1 - Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma

AU - Zhao, Lina

AU - Xu, Man

AU - Jiang, Wen

AU - Pan, Haitao

AU - Zang, Jian

AU - Luo, Shanquan

AU - Wang, Jianhua

AU - Zhou, Yongchun

AU - Shi, Mei

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: The role of induction chemotherapy is less clear in non-endemic locally advanced nanopharyngeal carcinomas (NPC). Results: With a total of 233 eligible patients and a median follow-up of 36 months, 3-year overall survival (OS), local recurrence-free survival (LRFS), distant metastasisfree survival (DMFS), disease free survival (DFS) were 84.5%, 94.9%, 78.6% and 69.2%, respectively. The overall failure rate was 21.0% and distant metastasis occurred in 17.2% patients. Multivariate analyses showed that retropharyngeal and bilateral neck lymph node metastasis were significant prognostic factors for DFS and OS. Moreover, patients receiving both GP (gemcitabine+cisplatin) and TP (docetaxel+cisplatin) regimes had significantly higher DFS and OS compared with PF (cisplatin+5-FU) regime. GP regimes lead to significantly improved OS than TP/PF in some subgroup of patients. No severe toxicities were observed. Materials and Methods: We retrospectively analyzed stage III-IVb NPC patients treated between Jan 2006 and Dec 2014, with induction chemotherapy followed by concurrent chemoradiation (IC-CCRT). Statistical analyses were performed on survival and failure patterns. Conclusions: These results suggested IC-CCRT was safe and effective for NPCs from non-endemic region. The choice of induction regimen appeared to affect patient outcomes.

AB - Background: The role of induction chemotherapy is less clear in non-endemic locally advanced nanopharyngeal carcinomas (NPC). Results: With a total of 233 eligible patients and a median follow-up of 36 months, 3-year overall survival (OS), local recurrence-free survival (LRFS), distant metastasisfree survival (DMFS), disease free survival (DFS) were 84.5%, 94.9%, 78.6% and 69.2%, respectively. The overall failure rate was 21.0% and distant metastasis occurred in 17.2% patients. Multivariate analyses showed that retropharyngeal and bilateral neck lymph node metastasis were significant prognostic factors for DFS and OS. Moreover, patients receiving both GP (gemcitabine+cisplatin) and TP (docetaxel+cisplatin) regimes had significantly higher DFS and OS compared with PF (cisplatin+5-FU) regime. GP regimes lead to significantly improved OS than TP/PF in some subgroup of patients. No severe toxicities were observed. Materials and Methods: We retrospectively analyzed stage III-IVb NPC patients treated between Jan 2006 and Dec 2014, with induction chemotherapy followed by concurrent chemoradiation (IC-CCRT). Statistical analyses were performed on survival and failure patterns. Conclusions: These results suggested IC-CCRT was safe and effective for NPCs from non-endemic region. The choice of induction regimen appeared to affect patient outcomes.

KW - IMRT

KW - Induction chemotherapy

KW - Nasopharyngeal carcinoma

KW - Non-endemic region

KW - WHO II/III

UR - http://www.scopus.com/inward/record.url?scp=85010715574&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010715574&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.14279

DO - 10.18632/oncotarget.14279

M3 - Article

C2 - 28036270

AN - SCOPUS:85010715574

VL - 8

SP - 6763

EP - 6774

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 4

ER -